AOBP <135/85 mm Hg) in-clinic in patients receiving antihypertensive medication(s) but uncontrolled BP out-ofclinic by 24-hour ambulatory BP monitoring (ABPM; awake ≥135/85 mm Hg). We hypothesized that MUCH patients have greater out-of-clinic sympathetic activity compared with true controlled hypertensives. Patients being treated for hypertension were prospectively recruited after 3 or more consecutive clinic visits. All patients were evaluated by inclinic automated office BP, plasma catecholamines, and spot-urine/plasma metanephrines. In addition, out-of-clinic 24-hour ABPM, 24-hour urinary for catecholamines and metanephrines was done. Out of 237 patients recruited, 169 patients had controlled in-clinic BP of which 156 patients had completed ABPM. Seventy-four were true controlled hypertensives, that is controlled by clinic automated office BP and by out-of-clinic ABPM. The remaining 82 were controlled by clinic automated office BP, but uncontrolled during out-of-clinic ABPM, indicative of MUCH. After exclusion of 4 patients because of inadequate or lack of 24-hour urinary collections, 72 true controlled hypertensive and 80 MUCH patients were analyzed. MUCH patients had significantly higher out-of-clinic BP variability and lower heart rate variability compared with true controlled hypertensives, as well as higher levels of out-of-clinic urinary catecholamines and metanephrines levels consistent with higher out-of-clinic sympathetic activity. In contrast, there was no difference in in-clinic plasma catecholamines and spot-urine/plasma levels of metanephrines between the 2 groups, consistent with similar levels of sympathetic activity while in clinic. MUCH patients have evidence of heightened outof-clinic sympathetic activity compared with true controlled hypertensives, which may contribute to the development of MUCH. (Hypertension. 2019;73:132-141.
M asked hypertension in untreated hypertensive patients or masked uncontrolled hypertension (MUCH) in treated hypertensive patients is defined as controlled blood pressure (BP) in clinic measured by office BP (<130/80 mm Hg) or automated office BP monitor (AOBP; <135/85 mm Hg); but uncontrolled BP out-of-clinic as measured by 24-hour ambulatory BP monitoring (ABPM; overall ≥130/80 or awake ≥135/85 mm Hg) or home BP ≥130/80 mm Hg. 1 The prevalence of masked hypertension/MUCH is higher in prehypertensives, 2 blacks, 3,4 elderly, 5 and in patients with diabetes mellitus, [6] [7] [8] chronic kidney disease. 7, [9] [10] [11] [12] In addition, the prevalence of masked hypertension/MUCH is reported to be higher in pediatric renal transplant recipients 13, 14 and adult renal transplant recipients. 15 The prevalence of masked hypertension is higher in patients receiving antihypertensive treatment 6, 16, 17 with the prevalence of MUCH reported between 30% and 50%. 6, 7, 17, 18 In addition, MUCH has also been shown to be a precursor to sustained hypertension. 19 Masked hypertension/MUCH patients have shown to have higher levels of albuminuria 20, 21 and increased rates of diastolic dysfunction. 22 MUCH has shown to have greater allcause and cardiovascular mortality compared with controlled hypertension and sustained uncontrolled hypertension treated on medications. 23 Patients with masked hypertension/MUCH have been reported to have evidence of higher sympathetic tone assessed by microneurography while in-clinic compared with patients with controlled hypertension. 10, 24 No studies have assessed sympathetic activity in MUCH patients while out-of-clinic. Such an assessment would be important from a mechanistic standpoint as it is uncontrolled out-of-clinic BP that distinguishes the MUCH phenotype from true controlled hypertension which is, controlled BP both in-and out-of-clinic. We hypothesized that MUCH patients have greater out-ofclinic sympathetic activity compared with patients with true controlled hypertension, implicating heightened out-of-clinic sympathetic tone as a cause of MUCH. To test this hypothesis, we prospectively compared indices of in-clinic sympathetic activity plasma catecholamines and spot-urine/plasma metanephrines in patients with confirmed MUCH with true controlled hypertensive patients. Indices of out-of-clinic sympathetic activity include 24-hour ambulatory BP 25 and heart rate (HR) variability 26 ; 24-hour urinary catecholamines and metanephrines which are compared in MUCH and true controlled hypertensive patients.
Methods
Data will be made available on request. It will be made available 1 year after completion of funding grant, so April 2020.
Study Population
Consecutive hypertensive patients on medications referred to the University of Alabama at Birmingham Hypertension Clinic were prospectively recruited between April 2014 and June 2018. Patients were enrolled after having been seen by a hypertension specialist for a minimum of 3 follow-up visits. All study patients were evaluated for secondary causes of hypertension, including hyperaldosteronism, pheochromocytoma, and renal artery stenosis, as medically indicated. Pregnant patients and patients with chronic kidney disease stage 4 or 5 (estimated glomerular filteration rate <30 mL/min per 1.73 m 2 ), patients suspected of nonadherence, based on self-report or low medication refill rates, were excluded. The study was approved by the University of Alabama at Birmingham Institutional Review Board, and written informed consent was obtained from all participants.
BP Measurement

Clinic AOBP
The clinic AOBP was measured using the BpTRU device, which automatically obtains 6 serial BP readings, 1 minute apart, before displaying the average of the last 5 readings. AOBP was measured after at least 5 minutes of quiet rest in a sitting position with the back supported and the arm supported at heart level. 27 These assessments were unattended, that is, unobserved in clinic. [28] [29] [30] [31] [32] An appropriate sized cuff was used with the cuff bladder encircling at least 80% of the arm. 32, 33 A BP cutoff of ≥135/85 mm Hg for elevated BP was used based on literature validating automated BP devices. 16, 34 Out-of-Clinic 24-Hour ABPM Study patients had an ABPM done using an automated, noninvasive, oscillometric device (Oscar 2; Suntech Medical Inc, Morrisville, NC). 1, 35 ABPM measurements were done every 20 minutes during the daytime (awake) and every 30 minutes during the nighttime (asleep). Awake and asleep times were determined by patient self-report. ABPM was determined to be valid if >80% of measurements were successful. All patients were counseled to take all antihypertensive medications and not to exercise while during their 24-hour ABPM period. Controlled ambulatory BP was defined as mean daytime (awake) BP <135/80 mm Hg. 1, 35 Awake, asleep, and 24-hour ambulatory BP (systolic and diastolic) and HR variability were calculated.
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Complete 24-Hour Urine Collection
The creatinine excretion rate was used to determine the completeness of urine collections. Urine samples with a creatinine excretion rate of 15 to 25 mg/kg per day for men and 10 to 20 mg/kg per day for women were considered complete. 37 To account for extremes in body sizes, incomplete collections were further evaluated. Measured creatinine clearance was compared with an expected creatinine clearance using the Cockcroft-gault formula with adjustments for body surface area. After review of incomplete urine collections, participants who had a measured creatinine clearance within 10% of the expected clearance were included back in the analysis data.
Biochemical Testing
Renal Function Panel, Serum Aldosterone, and Plasma Renin Activity Serum electrolytes, blood urea nitrogen, serum creatinine, serum aldosterone, and plasma renin activity were done according to routine laboratory methods. Serum aldosterone was analyzed by liquid chromatography-tandem mass spectrometry using multiple reaction monitoring in the negative mode, 38 and plasma renin activity is measured by high-performance liquid chromatography-electrospray-tandem mass spectrometry 39 (Mayo Medical Laboratories, Rochester, MN). 
Catecholamines and Metanephrines
Catecholamines and Metanephrines Tested in Clinic
Urine Metanephrines in Clinic. A spot urine collection was provided by all study participants in-clinic on the same day of completion of 24-hour urine collection. The first urine was voided, and subsequent urine was collected while patients were in the clinic. The spot urine was used for determination of metanephrines (metanephrine, normetanephrine, and total metanephrines) levels by reverse phase liquid chromatography-tandem mass spectrometry stable isotope dilution analysis (Mayo Medical Laboratories, Rochester, MN). 40, 41 Values are reported in microgram (µg) of metanephrine or normetanephrine per gram (g) of urine creatinine.
Plasma Catecholamines and Metanephrines in Clinic.
Blood samples were collected from all study patients during the same clinic visit as spot urine collection. These samples were used for determination of plasma catecholamines (epinephrine, norepinephrine, and total catecholamines) and metanephrines (metanephrine and normetanephrine). Plasma catecholamines were detected by high-performance liquid chromatography with electrochemical detection, 42 and plasma metanephrines levels were determined by liquid chromatography-tandem mass spectrometry (Mayo Medical Laboratories, Rochester, MN). 40 
Out-of-Clinic 24-Hour Urine Catecholamines and Metanephrines
Study participants completed an out-of-clinic 24-hour urine collection for determination of catecholamines (epinephrine, norepinephrine, and total catecholamines) and metanephrines (metanephrine, normetanephrine, and total metanephrines). Urinary catecholamines were determined by liquid chromatography with amperometric detection. 43 Urinary metanephrines were determined by reverse phase liquid chromatography-tandem mass spectrometry stable isotope dilution analysis (Mayo Medical Laboratories, Rochester, MN) 40, 41 with values reported as µg per 24-hour.
Statistical Analysis
Descriptive analyses were performed to summarize the demographics, comorbidities, and biochemical characteristics of study participants. Two sample t tests were used to detect the difference in antihypertensive medications, BP values, and biochemical (urine/ plasma catecholamines and metanephrines) variables between the true controlled hypertension and MUCH groups.
Linear mixed models were fitted to the BP and HR data, separately, to determine BP and HR variability, respectively. 44, 45 Each model incorporated subject-specific random intercepts. BP and HR variance were computed for participants with true controlled versus masked uncontrolled hypertension. Statistical significance of difference between these variance estimates was assessed. 36 Multivariable linear regression models were used to assess the relationship between BP and HR variability; in-clinic and out-of-clinic urinary/plasma catecholamines and metanephrines in hypertension groups adjusted for diabetes mellitus, body mass index (BMI), smoking, and use of calcium channel blockers, β-blockers, α-β-blockers, and α2-agonists.
All analyses were performed using SAS version 9.4 and R version 3.5.0. A P value <0.05 was considered statistically significant for 2-sided tests.
Results
Two hundred thirty-seven hypertensive patients were prospectively recruited after 3 or more consecutive clinic visits. Of these patients, 169 had controlled in-clinic BP while receiving antihypertensive medications (Figure 1 ).
Masked Uncontrolled Hypertension Prevalence
Of the 169 patients with controlled in-clinic BP (AOBP <135/85 mm Hg) on antihypertensive medications, 156 had adequate ABPM readings. Of these, 74 (47.4%) had Figure 1 ).
Completeness of 24-Hour Urine Collections
Out of the 74 patients with true controlled hypertension and 82 patients with confirmed MUCH, 4 patients were excluded because of inadequate or lack of 24-hour urine collections, such that the final analysis included 72 patients with true controlled hypertension and 80 MUCH patients. (Figure 1 ). 
Patient Characteristics
Antihypertensive Medications
The number of prescribed antihypertensive medications was similar for both groups (3.3±1.2 for patients with true controlled hypertensive and 3.6±1.2 for MUCH patients). There was no significant difference between the types of antihypertensive medication classes between true controlled and MUCH groups except that MUCH patients (27.8%) were on a significantly higher number of α-β-blockers (carvedilol and labetalol) than the true controlled hypertensive patients (13.4%; P=0.034; Table 1 ). Tables 2 and 3 ). Tables 2 and 3) . MUCH patients had significantly higher out-of-clinic awake, asleep and 24-hour ambulatory BP (systolic and diastolic) variability and lower HR variability compared with true controlled hypertensive patients (Tables 2 and 3 ). These differences persisted after multiple linear regression adjustment for diabetes mellitus, BMI, smoking, and use of calcium channel blockers, β-blockers, α-β-blockers, and α2-agonists (Table 4) .
BP Measurements In-and Out-of-Clinic
Out-of-Clinic BP Measurements by ABPM
Biochemical Evaluation-In-Clinic and Out-ofClinic Catecholamines and Metanephrines Levels
In-Clinic Catecholamines and Metanephrines Levels
There was no evidence of difference between the in-clinic spot urinary metanephrine, normetanephrine, and total metanephrines levels in true controlled hypertensive and MUCH study groups. In-clinic plasma epinephrine, norepinephrine, total catecholamines, metanephrine, and normetanephrine levels were also similar in both study groups (Tables 2 and 3 ; Figure 2 ). An absence of significant differences persisted between the groups after multiple linear regression adjustment for diabetes mellitus, BMI, smoking, and use of calcium channel blockers, β-blockers, α-β-blockers, and α2-agonists (Table 4) . 
Out-of-Clinic Catecholamines and Metanephrine Levels
Patients with MUCH had significantly higher levels of outof-clinic 24-hour urinary excretion rates of norepinephrine (P=0.032), total catecholamines (P=0.030), metanephrine (P=0.030), normetanephrine (P=0.017), and total metanephrines (P=0.008) compared with true controlled hypertensive patients (Tables 2 and 3 ; Figure 2 ). These differences persisted after multiple linear regression adjustment for diabetes, BMI, smoking, and use of calcium channel blockers, β-blockers, α-β-blockers, and α2-agonists (Table 4) .
Discussion
This is the first study to prospectively compare in-and out-ofclinic sympathetic activity in patients with MUCH versus a comparator group of true controlled hypertensive patients. The results provide evidence of higher out-of-clinic sympathetic activity in MUCH patients compared with patients with true controlled hypertension. Grassi et al 24 measured muscle sympathetic nerve activity from the peroneal nerve with use of microneurography and beat-to-beat arterial pressure at rest and during baroreceptor deactivation and activation in masked hypertensive and normotensive individuals in the clinic. Resting muscle sympathetic nerve activity in masked hypertensive patients was greater than in normotensive control individuals. Compared with normotensive subjects, baroreflex control of HR was significantly attenuated in masked hypertensive patients, whereas baroreflex-sympathetic control was unaffected. Homeostasis model assessment index was increased in patients in masked hypertension in direct relation with resting sympathetic nerve traffic, suggesting that masked hypertension is characterized by baseline sympathetic hyperactivity when assessed in the clinic setting. Plasma norepinephrine values obtained in the clinic were not significantly different between the 2 groups.
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Figure 2. Catecholamines (epinephrine, norepinephrine, and total catecholamines) and metanephrines (metanephrine, normetanephrine, and total metanephrines) level comparison between controlled and masked uncontrolled hypertension.
Agarwal et al
10 assessed sympathetic tone in chronic kidney disease patients with MUCH by measuring BP during graded symptom-limited exercise with a cycle ergometer and 7 minutes of recovery postexercise. During recovery, the healthy control group had a 5.9% decline in systolic BP per minute, while MUCH patients had only a 3.3% per minute reduction in systolic BP. This difference was interpreted to indicate less withdrawal of sympathetic tone on termination of exercise, resulting in vasoconstriction and delayed systolic BP recovery in the patients with MUCH, suggesting increased sympathetic tone a cause of MUCH. 10 Thus the findings of Grassi et al 24 and Agarwal et al 10 provide evidence that patients with masked hypertension/MUCH have greater sympathetic activity while in the clinic (or the laboratory) compared with controlled hypertensive patients. However, in neither study was sympathetic activity assessed while study patients were out-of-clinic, when BP levels are by definition higher, consistent with the MUCH phenotype.
The current study was designed to compare both in-clinic and out-of-clinic sympathetic activity in patients with MUCH versus a comparator group of patients with true controlled hypertension. The in-clinic sympathetic tone was indexed by plasma catecholamines and urinary/plasma metanephrines levels, which were similar in the 2 study groups. In contrast, higher out-of-clinic sympathetic tone as evidenced by higher BP variability and lower HR variability in MUCH patients; similarly, sympathetic tone indexed by 24-hour urinary catecholamines and metanephrines levels were significantly higher in the MUCH patients compared with true controlled hypertension.
Obesity and diabetes mellitus have been shown to increase sympathetic output. [46] [47] [48] [49] [50] In the current study, there was no significant difference in BMI between the MUCH and controlled hypertensive groups. Diabetes mellitus, however, was more common in the MUCH patients compared with controls (41.8% versus 22.4%, respectively). Smoking, antihypertensive medication classes like calcium channel blockers, β-blockers, α-β-blockers, and α2-agonists (clonidine and guanfacine) affect sympathetic output. MUCH patients were on significantly more α-β-blockers than patients with true controlled hypertension. While smoking, antihypertensive medication classes, including calcium channel blockers, β-blockers, and α2-agonists (clonidine and guanfacine) were similar in both the groups.
Multiple linear regression adjustment for diabetes mellitus, BMI, smoking, and use of calcium channel blockers, β-blockers, α-β-blockers, and α2-agonist show significantly higher out-of-clinic BP variability, lower out-of-clinic HR variability (Table 4) , and higher catecholamines/metanephrines levels in MUCH patients compared with controlled hypertensive patients (Table 4) , suggesting persistent increases in sympathetic tone unrelated to smoking, obesity, diabetes mellitus, and sympatholytic medications. Multiple linear regression adjustment for diabetes mellitus, BMI, smoking, and use of calcium channel blockers, β-blockers, α-β-blockers, and α2-agonists showed similar in-clinic catecholamines and metanephrines levels in MUCH patients compared with controlled hypertensive patients (Table 4) .
These findings provide for the first time evidence of increased out-of-clinic sympathetic output as an important cause of MUCH (Figure 3 ). If confirmed, these findings suggest that therapeutic strategies, including centrally acting agents that specifically target sympathetic output, might be beneficial in blunting or reversing the masked effect.
Strengths of the current study include its prospective design; inclusion of a diverse and relatively large cohort; rigorous definition of MUCH and true controlled hypertension; comparison of MUCH patients to a comparator group of true controlled hypertension; and measurement of both in-and out-of-clinic BP levels and sympathetic activity.
Study weaknesses include indexing sympathetic tone indirectly by measurement of catecholamines and metanephrines levels as opposed to a more direct method, such as with microneurography. Microneurography, however, is limited to the in-clinic setting.
Patients with MUCH have evidence of heightened outof-clinic sympathetic activity compared with true controlled hypertensive patients. These findings suggest that heightened out-of-clinic sympathetic activity contributes to the development of MUCH. If so, such patients may preferentially benefit 
Perspectives
Patients with MUCH have evidence of heightened out-of-clinic sympathetic activity compared with true controlled hypertensive patients suggesting that heightened out-of-clinic sympathetic activity contributes to the development of MUCH. If so, such patients may preferentially benefit from medications or interventional procedures that target sympathetic output and help in the management of MUCH and prevent increased cardiovascular, renal, and cerebrovascular risk associated with it.
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